Bridgewater Associates LP Has $629,000 Stock Position in Haemonetics Co. (NYSE:HAE)

Bridgewater Associates LP lessened its holdings in shares of Haemonetics Co. (NYSE:HAE) by 82.0% during the third quarter, Holdings Channel.com reports. The institutional investor owned 7,826 shares of the medical instruments supplier’s stock after selling 35,747 shares during the quarter. Bridgewater Associates LP’s holdings in Haemonetics were worth $629,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of HAE. Quarry LP acquired a new stake in shares of Haemonetics during the 2nd quarter worth about $39,000. Daiwa Securities Group Inc. bought a new position in Haemonetics in the 2nd quarter valued at about $82,000. Canada Pension Plan Investment Board acquired a new stake in Haemonetics during the second quarter worth approximately $83,000. Nisa Investment Advisors LLC grew its position in shares of Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 632 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Haemonetics during the second quarter worth approximately $140,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. BTIG Research initiated coverage on Haemonetics in a research note on Tuesday, September 10th. They issued a “buy” rating and a $112.00 price target for the company. CL King initiated coverage on shares of Haemonetics in a research note on Friday, September 13th. They issued a “buy” rating and a $116.00 price target on the stock. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective for the company in a research note on Friday, November 8th. Bank of America initiated coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $112.00 price target on shares of Haemonetics in a research report on Friday, November 15th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $107.88.

Haemonetics Stock Up 0.0 %

NYSE HAE opened at $87.48 on Tuesday. Haemonetics Co. has a fifty-two week low of $70.25 and a fifty-two week high of $97.97. The business has a fifty day moving average price of $80.21 and a two-hundred day moving average price of $82.00. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09. The stock has a market capitalization of $4.39 billion, a PE ratio of 36.30, a PEG ratio of 1.36 and a beta of 0.32.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.03. The business had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. Haemonetics’s revenue was up 8.6% compared to the same quarter last year. During the same period last year, the firm posted $0.99 earnings per share. Equities analysts expect that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.